Form 4: Bioxytran Director Dale Conaway Executes Stock Conversion
SEC Form 4 Filing
Director Dale Conaway converted common stock into convertible preferred stock in Bioxytran, Inc.
Summary
- On August 16, 2024, Director Dale Conaway acquired 123,967 shares of common stock at $0.121 per share.
- On August 19, 2024, Conaway disposed of 1,060,089 shares of common stock and acquired 212,018 shares of preferred stock at $0.835 per share.
- The transactions involved a 5:1 exchange of common stock into convertible preferred stock, with a conversion ratio of 1:5 into common stock.
Sentiment
Score: 5
Explanation: The document is a routine filing of stock transactions. The sentiment is neutral as it simply reports facts without expressing any opinion or forward-looking statements.
Positives
- The conversion to preferred stock may indicate a long-term commitment by the director.
Risks
- The impact of the stock conversion on the market price is uncertain.
Industry Context
Stock conversions are a common financial maneuver, often used to restructure equity or provide different rights to shareholders.
Stakeholder Impact
- Shareholders may be impacted by the change in the company's capital structure.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Acquisition of 123,967 shares of common stock |
| 08/19/2024 | Conversion of 1,060,089 shares of common stock into 212,018 shares of preferred stock |
| 08/20/2024 | Date of signature for the Form 4 filing |
Keywords
Bioxytran, BIXT, Director, Conaway, Stock Conversion, Preferred Stock, Common Stock, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.